


IN THE CLAIMS

1. (currently amended) A ~~fully and partially reduced~~ benzo(c)quinolizine compound of formula (1):



wherein:

R₁, R₂, R₃, R₄ and R₆, which are the same or different, are chosen from the group consisting of: H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, ~~canphane~~ camphane, adamantane, phenyl, biphenyl, naphthyl, or naphthyl-C₁₋₈;

R₅ is chosen from the group consisting of: H, C₁₋₈ alkyl, C₁₋₈ alkyl-phenyl, biphenyl, naphthyl, COOR, CN or phenyl,;

X is chosen from the group consisting of: O, C(=O)R, COOR, NO₂, and CONNR', wherein R and R' are the same or different and are chosen from the group consisting of H, C₁₋₈ alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norborane, camphane, adamantane, phenyl, biphenyl, naphthyl as ~~above~~ defined;

Q is chosen from the group consisting of single-bond, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, CO, CONR, and NR, where R is as above defined;

W is chosen from the group consisting of H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane,

cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, trifluoromethyl, C₁₋₈ alkoxy, C₁₋₈ alkoxy-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl, phenyloxy, biphenyloxy, naphthyloxy, phenylamino, biphenylamino, naphthylamino, C₁₋₈ alkyl-carbonyl, phenylcarbonyl, biphenylcarbonyl, naphthylcarbonyl, phenylcarboxyl, biphenylcarboxyl, naphthylcarboxyl, phenylcarboxamide, biphenylcarboxamide, naphthylcarboxamide, halogen, CN, NRR', C₁₋₈ alkylamino;

n is an integer comprised between 1 and 4;

the symbol ----- means that the corresponding bonds a, b, c, d, e, f, g, h and i are single or double bonds, with the proviso that when b or f are a double bond, the group R₅ is absent; and their pharmaceutically acceptable salts ~~and esters~~.

2. (previously presented) A benzo(c)quinolizine compound of formula (1) according to Claim 1, wherein R₅ = H, C₁₋₈ alkyl-phenyl, biphenyl, naphthyl;

X = O, COOH;

Q = single bond, CO, CONR, NR, wherein R

is chosen from the group consisting of H, C₁₋₈ alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl, naphthyl or naphthyl-C₁₋₈alkyl;

W = H, F, Cl, Br, Me, t-butyl, C₁₋₈alkoxy, 2,5-dimethylhexyl, trifluoromethyl, 2,5-(di-trifluoromethyl)-phenyl, 4-methyloxy-phenyl, phenyl, phenyl-C₁₋₈alkyl, C₁₋₈alkylcarbonyl, phenylcarbonyl;

n = 1 and 2;

R₁, R₂, R₃, R₄ and R₆ = H, Me, CN, phenyl, COOR, CONRR', C(=O)R, wherein R and R' are the same or different and are chosen from the group consisting of H, C₁₋₈ alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl, naphthyl or naphthyl-C₁₋₈

8.

3. (previously presented) A benzo[c]quinolizine compound[[s]]

according to Claim 1 which is of the [[of]] the formula:

2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-(1H)-benzo[c]quinolizin-3-one;

8-chloro-2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-8-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-4-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-1-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-decahydro-(1H)-benzo[c]quinolizin-3-one;

8-chloro-2,3,4,4a,5,6,6a,7,8,9,10,10a-decahydro-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(1H)-benzo[c]quinolizin-3-one;

(4a α ,6a β ,10a α)-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH)-benzo[c]quinolizin-3-one;

[(4a α ,6a β ,10a α)-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH)-benzo[c]quinolizin-3-one;]

3,4,5,6,6a,7,8,9,10,10a-decahydro-(1H)-benzo[c]quinolizin-3-one;

8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH)-benzo[c]quinolizin-3-one;

3,4,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-(4aH)-benzo[c]quinolizin-3-one;

3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(4aH)-benzo[c]quinolizin-3-one;

3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(4aH)-benzo[c]quinolizin-3-one;

8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,5,6,6a,7,8,9,10,10a-decahydro-4,8-dimethyl-(1H)-

benzo[c]quinolizin-3-one;
8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(1H) -
benzo[c]quinolizin-3-one;
2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4-dimethyl-(1H) -
benzo[c]quinolizin-3-one;
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(4aH) -
benzo[c]quinolizin-3-one;
3,4,5,6,6a,7,8,9,10,10a-decahydro-4,8-dimethyl-(4aH) -
benzo[c]quinolizin-3-one;
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(4aH) -
benzo[c]quinolizin-3-one;
3,4,5,6,6a,7,8,9,10,10a-decahydro-1,8-dimethyl-(4aH) -
benzo[c]quinolizin-3-one;
2,3,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(1H) -
benzo[c]quinolizin-3-one;
8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(1H) -
benzo[c]quinolizin-3-one;
2,3,5,6,6a,7,8,9,10,10a-decahydro-5,8-dimethyl-(1H) -
benzo[c]quinolizin-3-one;
2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(1H) -
benzo[c]quinolizin-3-one;
2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(1H) -
benzo[c]quinolizin-3-one;
3,4,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(4aH) -
benzo[c]quinolizin-3-one;
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(4aH) -
benzo[c]quinolizin-3-one;
3,4,5,6,6a,7,8,9,10,10a-decahydro-5,8-dimethyl-(4aH) -
benzo[c]quinolizin-3-one;
3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(4aH) -
benzo[c]quinolizin-3-one;
3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(4aH) -
benzo[c]quinolizin-3-one;
8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(1H) -
benzo[c]quinolizin-3-one;
2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,8-trimethyl-(1H) -
benzo[c]quinolizin-3-one;

8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4,5-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-6-methyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-6-methyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-6,8-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-6,8-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,6,8-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(4aH) -

benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,6,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,6,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-5,6,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,6,8-tetramethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4,5,6-tetramethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;

3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,6,8-tetramethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,6,8-tetramethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 5,6,6a,7,8,9,10,10a-octahydro-(3H) -benzo[c]quinolizin-3-one;
 8-chloro-5,6,6a,7,8,9,10,10a-octahydro-(3H) -benzo[c]quinolizin-3-
 one;
 5,6,6a,7,8,9,10,10a-octahydro-8-methyl-(3H) -benzo[c]quinolizin-3-
 one;
 5,6,6a,7,8,9,10,10a-octahydro-4-methyl-(3H) -benzo[c]quinolizin-3-
 one;
 8-chloro-5,6,6a,7,8,9,10,10a-octahydro-4-methyl-(3H) -
 benzo[c]quinolizin-3-one;
 5,6,6a,7,8,9,10,10a-octahydro-4,8-dimethyl-(3H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,7,8,9,10-octahydro-(1H) -benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,7,8,9,10-octahydro-(1H) -benzo[c]quinolizin-3-
 one;
 2,3,5,6,7,8,9,10-octahydro-8-methyl-(1H) -benzo[c]quinolizin-3-
 one;
 2,3,5,6,6a,7,8,9-octahydro-(1H) -benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9-octahydro-(1H) -benzo[c]quinolizin-3-
 one;
 2,3,5,6,6a,7,8,9-octahydro-8-methyl-(1H) -benzo[c]quinolizin-3-
 one;
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH) -
 benzo[c]quinolizin-3-one;
 4a-benzyl-8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH) -
 benzo[c]quinolizin-3-one;
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-(4aH) -
 benzo[c]quinolizin-3-one;
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(4aH) -
 benzo[c]quinolizin-3-one;
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(4aH) -
 benzo[c]quinolizin-3-one;

3,4,5,6,6a,7,8,9,10,10a-decahydro-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one;
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4a-(4-pyridyl)-methyl-(4aH)-benzo[c]quinolizin-3-one;
3,4,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one;
3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one[;]_
3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one;

4. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (canceled)

10. (previously presented) A pharmaceutical composition wherein the active principle is a compound of formula (I) according to Claim 1 or mixtures thereof in combination with suitable pharmaceutically acceptable excipients.

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)


24. (canceled)

25. (canceled)

26. (canceled)

27. (currently amended) A method for the inhibition of a pathology caused by 5 α reductase-I and/or 5 α reductase-II isoenzymes in an afflicted host as defined in claim 13 where the pathology is selected from the group consisting of acne, baldness, prostatic cancer and prostatic hypertrophy in men and hirsutism in women, said method comprising administering an effective amount of a compound of claim 1 to an afflicted host.

28. (amended) A ~~fully and partially reduced~~ benzo(c)quinolizine compound of formula (1):



wherein:

R₁, R₂, R₃, R₄ and R₆, which are the same or different, are chosen from the group consisting of: H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, phenyl, biphenyl or naphthyl;

R₅ is chosen from the group consisting of: H, C₁₋₈ alkyl, C₁₋₈alkyl-phenyl, biphenyl, naphthyl, COOR, CN or phenyl;

X is chosen from the group consisting of: O, C(=O)R, COOR, NO₂, and CONNR', wherein R and R' are the same or different and are chosen from the group consisting of H, C₁₋₈ alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norborane, camphane, adamantane, phenyl, biphenyl, naphthyl as above defined;

Q is chosen from the group consisting of single-bond, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane,


camphane, adamantane, CO, CONR, and NR, where R is as above defined;

W is chosen from the group consisting of H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, trifluoromethyl, C₁₋₈ alkoxy, C₁₋₈ alkoxy-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl, phenyloxy, biphenyloxy, naphthyloxy, phenylamino, biphenylamino, naphthylamino, C₁₋₈ alkyl-carbonyl, phenylcarbonyl, biphenylcarbonyl, naphthylcarbonyl, phenylcarboxyl, biphenylcarboxyl, naphthylcarboxyl, phenylcarboxamide, biphenylcarboxamide, naphthylcarboxamide, halogen, CN, NRR' where R and R' are as above defined;

n is an integer comprised between 1 and 4;

the symbol ----- means that the corresponding bonds a, b, c, d, e, f, g, h and i are single or double bonds, with the proviso that when b or f are a double bond, the group R₅ is absent; and their pharmaceutically acceptable salts ~~and esters~~.

29. (currently amended) A ~~fully and partially reduced~~ benzo(c)quinolizine compound of formula (1):



wherein:

R₁, R₂, R₃, R₄ and R₆, which are the same or different, are chosen from the group consisting of: H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, phenyl, biphenyl or naphthyl;

R₅ is chosen from the group consisting of: H, C₁₋₈ alkyl, C₁₋₈ alkyl-phenyl, biphenyl, naphthyl, COOR, CN, phenyl;
X is chosen from the group consisting of: O, C(=O)R, COOR, NO₂, and CONNR', wherein R and R' are the same or different and are chosen from the group consisting of H, C₁₋₈ alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norborane, camphane, adamantane, phenyl, biphenyl, naphthyl as above defined;
Q is chosen from the group consisting of single-bond, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, CO, CONR, and NR, where R is as above defined;
W is chosen from the group consisting of H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, trifluoromethyl, C₁₋₈ alkoxy, C₁₋₈ alkoxy-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl, phenyloxy, biphenyloxy, naphthyloxy, phenylamino, biphenylamino, naphthylamino, C₁₋₈ alkyl-carbonyl, phenylcarbonyl, biphenylcarbonyl, naphthylcarbonyl, phenylcarboxyl, biphenylcarboxyl, naphthylcarboxyl, phenylcarboxamide, biphenylcarboxamide, naphthylcarboxamide, halogen, CN, NRR', C₁₋₈ alkylamino;
n is an integer comprised between 1 and 4;
the symbol ----- means that the corresponding bonds a, b, c, d, e, f, g, h and i are single or double bonds, with the proviso that when b or f are a double bond, the group R₅ is absent; and their pharmaceutically acceptable salts ~~and esters~~.

REMARKS

In the Office Action, the Examiner objected to claim 1 as being a substantial duplicate of claims 28 and 29.

Reconsideration is requested.

Claim 1 defines R¹, R₂, R₃, R₄ and R₆ as including